Cover Image
市場調查報告書

Saniona AB.的產品平台分析

Saniona AB - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 341862
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
Saniona AB.的產品平台分析 Saniona AB - Product Pipeline Review - 2016
出版日期: 2016年08月17日 內容資訊: 英文 55 Pages
簡介

Saniona AB 是開發中樞神經系統疾病和自體免疫疾病、止痛藥的研究開發型的企業。該公司主要提供思覺失調症和老年癡呆症、重度憂鬱症、神經性疼痛、發炎等領域的產品。

本報告提供Saniona AB 的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估及中止的計劃相關資訊等。

Saniona AB的基本資料

  • Saniona AB概要
  • 主要資訊
  • 企業資料

Saniona AB:R&D概要

  • 主要的治療範圍

Saniona AB:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Saniona AB:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Saniona AB:藥物簡介

Saniona AB:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Saniona AB:最近的開發平台趨勢

Saniona AB:暫停中的計劃

Saniona AB:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • N-S2359
    • tesofensine

Saniona AB:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08121CDB

Summary

Global Markets Direct's, 'Saniona AB - Product Pipeline Review - 2016', provides an overview of the Saniona AB's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Saniona AB, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Saniona AB
  • The report provides overview of Saniona AB including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Saniona AB's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Saniona AB's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Saniona AB's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Saniona AB
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Saniona AB's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Saniona AB Snapshot
    • Saniona AB Overview
    • Key Information
    • Key Facts
  • Saniona AB - Research and Development Overview
    • Key Therapeutic Areas
  • Saniona AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Saniona AB - Pipeline Products Glance
    • Saniona AB - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Saniona AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Saniona AB - Drug Profiles
    • (metoprolol + tesofensine)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NS-2359
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tesofensine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-721
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-788
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-346
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-470
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-761
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NS-9283
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize GABAA Alpha 2 and Alpha 3 for Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize nAChR Alpha7 for Pain and Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate TREK for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize GABA Alpha 4 Delta Receptor for Sleep Disorders, Stress and Autism
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize nAChR Alpha6 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Block TREK for Depression
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Monoamine Reuptake for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Saniona AB - Pipeline Analysis
    • Saniona AB - Pipeline Products by Target
    • Saniona AB - Pipeline Products by Route of Administration
    • Saniona AB - Pipeline Products by Molecule Type
    • Saniona AB - Pipeline Products by Mechanism of Action
  • Saniona AB - Recent Pipeline Updates
  • Saniona AB - Dormant Projects
  • Saniona AB - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • NS-2359
      • tesofensine
  • Saniona AB - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Saniona AB, Key Information
  • Saniona AB, Key Facts
  • Saniona AB - Pipeline by Indication, 2016
  • Saniona AB - Pipeline by Stage of Development, 2016
  • Saniona AB - Monotherapy Products in Pipeline, 2016
  • Saniona AB - Combination Treatment Modalities in Pipeline, 2016
  • Saniona AB - Out-Licensed Products in Pipeline, 2016
  • Saniona AB - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Saniona AB - Phase II, 2016
  • Saniona AB - Phase I, 2016
  • Saniona AB - Preclinical, 2016
  • Saniona AB - Discovery, 2016
  • Saniona AB - Pipeline by Target, 2016
  • Saniona AB - Pipeline by Route of Administration, 2016
  • Saniona AB - Pipeline by Molecule Type, 2016
  • Saniona AB - Pipeline Products by Mechanism of Action, 2016
  • Saniona AB - Recent Pipeline Updates, 2016
  • Saniona AB - Dormant Developmental Projects,2016
  • Saniona AB - Discontinued Pipeline Products, 2016

List of Figures

  • Saniona AB - Pipeline by Top 10 Indication, 2016
  • Saniona AB - Pipeline by Stage of Development, 2016
  • Saniona AB - Monotherapy Products in Pipeline, 2016
  • Saniona AB - Combination Treatment Modalities in Pipeline, 2016
  • Saniona AB - Pipeline by Top 10 Target, 2016
  • Saniona AB - Pipeline by Route of Administration, 2016
  • Saniona AB - Pipeline by Molecule Type, 2016
  • Saniona AB - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top